IMA 950

Drug Profile

IMA 950

Alternative Names: IMA950

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator immatics biotechnologies GmbH
  • Developer Cancer Research UK; immatics biotechnologies GmbH; National Cancer Institute (USA); Oncovir; University Hospitals of Geneva
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Glioma

Most Recent Events

  • 06 Sep 2017 Immunogenecity and adverse events data from a phase I/II trial in Glioblastoma presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
  • 01 Jan 2017 Phase-I clinical trials in Glioma (Neoadjuvant therapy, Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02924038)
  • 04 Oct 2016 University of California at San Francisco plans a pilot phase I trial for Glioma (Combination therapy, Second-line therapy or greater, Neoadjuvant therapy) in USA (SC) (NCT02924038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top